Dihydroartemisinin Disrupts Zinc Homeostasis in Plasmodium falciparum To Potentiate Its Antimalarial Action via Pyknosis

ACS Infect Dis. 2023 Jul 14;9(7):1303-1309. doi: 10.1021/acsinfecdis.3c00031. Epub 2023 Jun 15.

Abstract

Artemisinins have been used as first-line drugs worldwide to treat malaria caused by Plasmodium falciparum; however, its underlying mechanism is still unclear. This study aimed to identify the factors inducing growth inhibition via pyknosis, a state of intraerythrocytic developmental arrest, when exposing the parasite to dihydroartemisinin (DHA). Changes in the expression of genome-wide transcripts were assessed in the parasites treated with antimalarials, revealing the specific downregulation of zinc-associated proteins by DHA. The quantification of zinc levels in DHA-treated parasite indicated abnormal zinc depletion. Notably, the zinc-depleted condition in the parasite produced by a zinc chelator induced the generation of a pyknotic form and the suppression of its proliferation. The evaluation of the antimalarial activity of DHA or a glutathione-synthesis inhibitor in the zinc-depleted state showed that the disruption of zinc and glutathione homeostasis synergistically potentiated the growth inhibition of P. falciparum through pyknosis. These findings could help further understand the antimalarial actions of artemisinins for advancing malaria therapy.

Keywords: Plasmodium falciparum; dihydroartemisinin; zinc depletion; zinc homeostasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimalarials* / pharmacology
  • Artemisinins* / pharmacology
  • Folic Acid Antagonists*
  • Glutathione
  • Homeostasis
  • Humans
  • Malaria* / drug therapy
  • Malaria, Falciparum* / drug therapy
  • Parasites*
  • Plasmodium falciparum

Substances

  • Antimalarials
  • artenimol
  • Artemisinins
  • Folic Acid Antagonists
  • Glutathione